慢性骨髓增生性肿瘤患者心血管危险因素的再评价。

IF 1.1 Q4 ONCOLOGY Clinical Advances in Hematology & Oncology Pub Date : 2023-10-01

Ivan Krecak, Srdan Verstovsek, Marko Lucijanic

{"title":"慢性骨髓增生性肿瘤患者心血管危险因素的再评价。","authors":"Ivan Krecak, Srdan Verstovsek, Marko Lucijanic","doi":"","DOIUrl":null,"url":null,"abstract":"Cardiovascular (CV) risk factors are important contributors to thrombotic risk in the general population and in patients with chronic myeloproliferative neoplasms (MPNs). However, the role of CV risk factors is often masked by other disease features that have a strong prognostic impact regarding thrombotic risk in MPN patients. This review summarizes the contemporary knowledge and aspects that have not been addressed or lack consensus in the medical community. We propose multidisciplinary care for MPN patients with CV comorbidities and provide future directions that may be needed to appropriately manage CV risk factors in MPNs.","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"21 10","pages":"541-548"},"PeriodicalIF":1.1000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasms.\",\"authors\":\"Ivan Krecak, Srdan Verstovsek, Marko Lucijanic\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cardiovascular (CV) risk factors are important contributors to thrombotic risk in the general population and in patients with chronic myeloproliferative neoplasms (MPNs). However, the role of CV risk factors is often masked by other disease features that have a strong prognostic impact regarding thrombotic risk in MPN patients. This review summarizes the contemporary knowledge and aspects that have not been addressed or lack consensus in the medical community. We propose multidisciplinary care for MPN patients with CV comorbidities and provide future directions that may be needed to appropriately manage CV risk factors in MPNs.\",\"PeriodicalId\":51585,\"journal\":{\"name\":\"Clinical Advances in Hematology & Oncology\",\"volume\":\"21 10\",\"pages\":\"541-548\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Advances in Hematology & Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Advances in Hematology & Oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

心血管（CV）危险因素是普通人群和慢性骨髓增生性肿瘤（MPNs）患者血栓形成风险的重要因素。然而，CV风险因素的作用通常被其他疾病特征所掩盖，这些疾病特征对MPN患者的血栓形成风险具有很强的预后影响。这篇综述总结了医学界尚未解决或缺乏共识的当代知识和方面。我们建议对患有CV合并症的MPN患者进行多学科护理，并提供未来可能需要的指导，以适当管理MPN中的CV风险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasms.

Cardiovascular (CV) risk factors are important contributors to thrombotic risk in the general population and in patients with chronic myeloproliferative neoplasms (MPNs). However, the role of CV risk factors is often masked by other disease features that have a strong prognostic impact regarding thrombotic risk in MPN patients. This review summarizes the contemporary knowledge and aspects that have not been addressed or lack consensus in the medical community. We propose multidisciplinary care for MPN patients with CV comorbidities and provide future directions that may be needed to appropriately manage CV risk factors in MPNs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Advances in Hematology & Oncology ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： Clinical Advances in Hematology & Oncology (CAH&O) is a monthly peer-reviewed journal reaching more than 27,000 hematology and oncology clinicians. CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of today’s top thought leaders in hematology & oncology, including feature-length review articles, monthly columns consisting of engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, drug development, and clinical case studies with expert commentary. CAH&O also publishes industry-supported meeting highlights, clinical roundtable monographs, and clinical review supplements.

期刊最新文献

Recombinant ADAMTS13 concentrate in thrombotic thrombocytopenic purpura. Should ponatinib be the standard-of-care tyrosine kinase inhibitor in Ph+ ALL? Does combination menopausal hormone therapy increase the risk of breast cancer? Tackling the cancer drug shortage. Targeted therapy in prostate cancer: beyond PSMA.